ClinicalTrials.gg
CompletedNCT00116298Updated Apr 25, 2011

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

A Phase 3 interventional study of stavudine, efavirenz, lamivudine in HIV Infections and AIDS, sponsored by Bristol-Myers Squibb. Completed at 63 sites in 16 countries. Per ClinicalTrials.gov, last updated 2011-04-25.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's listed conditions name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing stavudine in Acquired Immunodeficiency Syndrome — none open to participants now, none under way, none of them phase 3. Stavudine · Acquired Immunodeficiency Syndrome.

Enrollment
3rd of 13
900 · median 230
Started
2001
the only one that year
Phase 3
3 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
4 of 14
Bristol-Myers Squibb

Among the 14 studies testing stavudine in Acquired Immunodeficiency Syndrome, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2001, is one of 3 in phase 3, and was the 9th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 14 studies testing stavudine in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About stavudine

Stavudine: first FDA approval 1994 (ZERIT), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing stavudine in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations, each in combination with lamivudine (3TC) and efavirenz (EFV) in subjects who have completed Bristol-Myers Squibb (BMS) studies AI455-096 and AI455-099.

03

Conditions studied

  • HIV Infections
  • AIDS

Browse trials for

Keywords

  • Antivirals
  • HIV
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 900 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed d4T studies AI455-096 or AI455-099
  • Have demonstrated compliance with the study medication and treatment visits
  • Provide written
  • Agree to use a barrier method of (such as condoms) during the study
  • Have a negative pregnancy test within 72 hours prior to start of study medication

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or breast-feeding
  • Need to take certain medications that have systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential
  • Have active alcohol or substance abuse which may prevent compliance or increase risk of developing pancreatitis
  • Have certain other conditions or prior treatments that might interfere with study continuation
  • Need to take certain medications that should not be taken with EFV
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants

Interventions

07

What researchers measure

Primary outcomes

  1. Safety: Frequency and severity of AEs, and treatment discontinuations for AEs; population trends for triglycerides and cholesterol. Primary efficacy outcome: proportion of subjects with HIVRNA <400, <50, and change in viral load over the study period

Secondary outcomes

  1. Efficacy: Changes in CD4 cell counts

08

Study locations

63 sites
  • Local Institution
    Berkeley, California, United States
  • Local Institution
    Los Angeles, California, United States
  • Local Institution
    West Hollywood, California, United States
  • Local Institution
    Washington, District of Columbia, United States
  • Local Institution
    Ft. Lauderdale, Florida, United States
  • Local Institution
    Orlando, Florida, United States
  • Local Institution
    Tampa, Florida, United States
  • Local Institution
    Indianapolis, Indiana, United States
  • Local Institution
    Wichita, Kansas, United States
  • Local Institution
    Louisville, Kentucky, United States
  • Local Institution
    Brookline, Massachusetts, United States
  • Local Institution
    Las Vegas, Nevada, United States
  • Local Institution
    Reno, Nevada, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Winston-Salem, North Carolina, United States
  • Local Institution
    Oklahoma City, Oklahoma, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Houston, Texas, United States
  • Local Institution
    Hampton, Virginia, United States
  • Local Institution
    San Isidro, Buenos Aires, Argentina
  • Local Institution
    Rosario, Santa Fe, Argentina
  • Local Institution
    Buenos Aires, Argentina
  • Local Institution
    Cordoba, Argentina
  • Local Institution
    Gent, Belgium
  • Local Institution
    Liege, Belgium
  • Local Institution
    Salvador, Bahia, Brazil
  • Local Institution
    Belo Horizonte - MG, Minas Gerais, Brazil
  • Local Institution
    Botucatu, Sao Paulo, Brazil
  • Local Institution
    Santos, Sao Paulo, Brazil
  • Local Institution
    Vancouver, British Columbia, Canada
  • Local Institution
    Toronto, Ontario, Canada
  • Local Institution
    Montreal, Quebec, Canada
  • Local Institution
    Bordeaux Cedex, France
  • Local Institution
    Lyon Cedex 03, France
  • Local Institution
    Nantes Cedex 01, France
  • Local Institution
    Paris Cedex 13, France
  • Local Institution
    Rennes Cedex 9, France
  • Local Institution
    Rehovot, Israel
  • Local Institution
    Tel Hashorner, Israel
  • Local Institution
    Bari, Italy
  • Local Institution
    Bergamo, Italy
  • Local Institution
    Firenze, Italy
  • Local Institution
    Milano, Italy
  • Local Institution
    Napoli, Italy
  • Local Institution
    Pisa, Italy
  • Local Institution
    Torino, Italy
  • Local Institution
    Mexico, Distrito Federal, Mexico
  • Local Institution
    Coimbra, Portugal
  • Local Institution
    Lisboa, Portugal
  • Local Institution
    Cotto Laurel, Puerto Rico
  • Local Institution
    San Juan, Puerto Rico
  • Local Institution
    Moscow, Russian Federation
  • Local Institution
    St. Petersburg, Russian Federation
  • Local Institution
    Singapore, Singapore
  • Local Institution
    Bedford Gardens, Gauteng, South Africa
  • Local Institution
    Hatfield, Gauteng, South Africa
  • Local Institution
    JOhannesburg, Gauteng, South Africa
  • Local Institution
    Westdene, Gauteng, South Africa
  • Local Institution
    Tygerberg, Western Cape, South Africa
  • Local Institution
    Barcelona, Spain
  • Local Institution
    Madrid, Spain
  • Local Institution
    Bangkok, Thailand
  • Local Institution
    Nontaburi, Thailand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Jan 2005 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2005
First posted
Jun 29, 2005
Start
Jan 2001
Primary completionActual
Jan 2005
CompletionActual
Jan 2005
Results delay requested
Jan 28, 2010
Last update
Apr 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00116298
First posted
Jun 29, 2005
Start date
Jan 2001
Primary completion
Jan 2005
Completion
Jan 2005
Last update
Apr 25, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Stavudine · Efavirenz · Lamivudine

Start the discussion